Drugs / XELAGLIFAM
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04982705 | Jul 2021 → Nov 2022 | type 2 diabetes mellitus | IlDong Pharmaceutical Co Ltd | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-04-21 | IlDong Pharmaceutical Co Ltd | Regulatory 일동제약, 유럽서 당뇨병 신약 임상계획 승인 신청 ildong.com ↗
일동제약(대표 윤웅섭)은 독일 연방 의약품·의료기기 관리 기관(BfArM)에 자사의 제2형 당뇨병 치료제 후보물질 ‘IDG-16177’ 임상 1상 시험 계획에 대한 승인을 신청했다고 21일 밝혔다. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-04-21 | IlDong Pharmaceutical Co Ltd | 일동제약, 유럽서 당뇨병 신약 임상계획 승인 신청 ildong.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XELAGLIFAM | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314448 ↗ |
| Known as | IDG-16177 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04982705 ↗ |
| Modality | Small molecule | — CHEMBL5314448 ↗ |
| Route | Oral | “Subjects will receive a single oral dose of IMP.” NCT04982705 ↗ |